Answers are grounded in this paper and cite their sources.
The mechanisms and signaling pathways by which acute and long-term administration of mu-opioid receptor agonists lead to a myriad of opioid effects are incompletely understood. The “life-cycle” of various signaling proteins and processes which may promote their “retirement” into a functionally inactive pool or their “re-utilization” could be important factors in attempts to modulate opioid signaling for optimal analgesia. G-protein-coupled receptors (GPCRs), G-pro-teins and G-protein subunit interactions, G-protein-coupled receptor kinases (GRKs), Dynamin II, G-protein-coupled receptor phosphatase (GRP), regulators of G-protein signaling (RGS), activators of G-protein signaling (AGS), ß-arrestin, and phosducin-like proteins may contribute to modulating mu-opioid receptor agonist effects. It appears that different opioid agents may utilize different pathways or regulators and have different affinities for these various proteins. Furthermore, the same opioid agent may act differently in different environments (e.g., local inflammation). A more complete appreciation of these processes, as well as their modulation may facilitate achieving maximal analgesic effects when utilizing opioids clinically to relieve pain.
No takes yet. Share an insight, caveat, or question.
Howard S. Smith (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: